Trial Information
A Non-interventional Survey on the Epidermal Growth Factor Receptor (EGFR) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology
Inclusion Criteria:
- Histological diagnosed as adenocarcinoma type of non-small cell lung cancer
- Have completed lung cancer operation
- The tumour EGFR gene mutation status test was performed as regular medical practice
Exclusion Criteria:
- Patients who disagree to participate this study
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
type and prevalence of EGFR mutation
Outcome Time Frame:
up to 3 months
Safety Issue:
No
Principal Investigator
Karen Atkin
Investigator Role:
Study Director
Investigator Affiliation:
Astrazeneca China R&D
Authority:
China: Food and Drug Administration
Study ID:
NIS-OCN-DUM-2009/1
NCT ID:
NCT01106781
Start Date:
August 2010
Completion Date:
December 2013
Related Keywords:
- Non-Small Cell Lung Cancer
- EGFR mutation test
- NSCLC
- Non-Interventional Study
- EGFR mutation status
- Adenocarcinoma
- Adenocarcinoma, Mucinous
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms